Fig. 1: Study Design and Participant Flow in a Phase I Trial of Hydroxychloroquine, Palbociclib, and Letrozole in HR+/HER2- Metastatic Breast Cancer. | npj Breast Cancer

Fig. 1: Study Design and Participant Flow in a Phase I Trial of Hydroxychloroquine, Palbociclib, and Letrozole in HR+/HER2- Metastatic Breast Cancer.

From: Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer

Fig. 1

A Study schema for dose escalation and dose expansion of hydroxychloroquine (HCQ) (400 mg, 600 mg, and 800 mg/day) in combination with fixed-dose continuous palbociclib (75 mg/day) and letrozole (2.5 mg/day). B Flow chart (CONSORT diagram) of study participants (enrollment and disposition).

Back to article page